Stockreport

NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]

NRX Pharmaceuticals, Inc.  (NRXP) 
PDF Research and Development Expense: Decreased by approximately $2.4 million to $3.8 million from $6.2 million year-over-year. General and Administrative Expense: Decrea [Read more]